Finally, given the tumor cell heterogeneity with respect to TRAIL-R2 expression within a tumor cell population, switching a physiological/uninflamed to an inflamed hepatic microenvironment might select for PDAC cells expressing TRAIL-R2, because these cells experience a fitness advantage under these particular conditions. This evidence concerns the gene TNFRSF10B and neoplasm.